Business
Press Release Jan 30 2026
Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of ₹2,359m in Q3FY26".
About this update from Strides Pharma Science Ltd
Strides Pharma Science Limited has informed the Exchange regarding a press release dated January 30, 2026, titled "Strides Continues to Deliver Exceptional Performance With Highest Ever Quarterly EBITDA of ₹2,359m in Q3FY26". View Attachment
View stock analysis, news, and events for Strides Pharma Science Ltd